Placebo + 30 mg Apremilast

DRUG2 trials

Sponsors

Amgen

Conditions

Psoriatic Arthritis

Phase 3

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

CompletedNCT01172938

AmgenPsoriatic Arthritis

Start: 2010-06-02End: 2016-10-27Updated: 2020-06-19

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

CompletedNCT01212757

AmgenPsoriatic Arthritis

Start: 2010-09-27End: 2017-01-25Updated: 2020-05-06

Related Papers

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome

American Journal of Clinical Dermatology2023-06-1440 citations

Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials.

PubMed2021-12-012 citations

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

Arthritis Research & Therapy2019-05-1076 citations

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies

RMD Open2018-06-0137 citations

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).

2016-12-19129 citations

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

The Journal of Rheumatology2016-07-15206 citations

Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis

The Journal of Rheumatology2015-01-15133 citations

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

2014-03-04302 citations